March 20, 2017 by
EMERGO SUMMARY OF KEY POINTS:
- The Trump Administration has proposed user fee increases for drug, medical device and other FDA registrants in 2018.
- Few specifics on the proposed increases make it difficult to determine exactly how medical device firms would be impacted.
- Smaller manufacturers make up the vast majority of the US medical device industry, and would be most substantially affected by higher FDA fees.
US Food and Drug Administration user fee increases in the Trump Administration’s proposed 2018 federal budget would disproportionately impact smaller medical device companies, as these firms make up the majority of the US medical device industry.
President Trump’s recently released budget blueprint for 2018 would adjust FDA user fees for 2018 to more than $2 billion, “approximately $1 billion over the 2017 annualized…level, and replaces the need for new budget authority to cover pre-market review costs.” These increases would be offset by administrative initiatives to boost regulatory efficiencies and speed up market authorization timeframes, according to the text of the proposed budget.